文档介绍：中国当代医药 年 月第 卷第 期
2021 2 28 5 ·m in the treat-
ment of advanced colorectal cancer
WU Yu-ling
Department of Oncology, the Third People's Hospital of Jingdezhen City, Jiangxi Province, Jingdezhen 333000, China
[Abstract] Objective
To compare the effect of Oxaliplatin combined with Capecitabine and Oxaliplatin combined with
Methods
Tegafur Gimeracil Oteracil Potassium in the treatment of advanced colorectal cancer. A total of 66 patients
with advanced colorectal cancer admitted to the Third People's Hospital of Jingdezhen City from August 2016 to Au-
gust 2017 were selected as the research subjects. According to the random number table method, they were divided into
n n
the Capecitabine group ( =33) and the Tegafur Gimeracil Oteracil Potassium group ( =33). In the Capecitabine group,
Oxaliplatin combined with Capecitabine was used, and in the Tegafur Gimeracil Oteracil Potassium group, Oxaliplatin
combined with Tegafur Gimeracil Oteracil Potassium was used for treatment. The clinical efficacy, adverse reactions